TABLE 1.

Key input parameters.

Input	Base-case value	Range	Distribution	References
Population event rates, %
Non-fatal MI	1.7	Age dependent	NA	Dreyer et al. (2019), National Health Commission of the People’s Republic of China (2019)
Non-fatal IS	0.9	Age dependent	NA	Dreyer et al. (2019), National Health Commission of the People’s Republic of China (2019)
Cardiovascular death	2.2	Age dependent	NA	Dreyer et al. (2019), National Health Commission of the People’s Republic of China (2019)
Non-cardiovascular death	0.9	Age dependent	NA	Dreyer et al. (2019), National Health Commission of the People’s Republic of China (2019)
Therapeutic effect based on clinical endpoints, HR
Non-fatal MI	0.86	0.77–0.96	Log normal	Schwartz et al. (2018)
Non-fatal IS	0.73	0.57–0.93	Log normal	Schwartz et al. (2018)
Cardiovascular death	0.88	0.74–1.05 a	Log normal	Schwartz et al. (2018)
Therapeutic effect based on LDL-C reduction, RR
Non-fatal MI	0.57	0.53–0.63	Log normal	Han et al. (2020), Baigent et al. (2010)
Non-fatal IS	0.66	0.59–0.75	Log normal	Han et al. (2020), Baigent et al. (2010)
Cardiovascular death	0.77	0.71–0.83	Log normal	Han et al. (2020), Baigent et al. (2010)
Annual cost of drugs, CNY
Alirocumab
Full list price	51,532	NA	NA	Calculated
Discounted net price	34,355	NA	NA	Calculated
Ezetimibe	2,827	NA	NA	Calculated
Cost of cardiovascular events, CNY b
Initial event-free	8,344	6,258–10,430	Log normal	Fu et al. (2020)
Non-fatal MI	71,030	53,272–88,787	Log normal	Wang et al. (2015)
Post-MI	8,344	6,258–10,430	Log normal	Fu et al. (2020)
Non-fatal IS	22,342	16,756–27,927	Log normal	Yin et al. (2018)
Post-IS	8,463	6,347–10,578	Log normal	Fu et al. (2020)
Death due to MI	87,756	65,817–109,695	Log normal	Wang et al. (2015)
Death due to stroke	59,025	44,269–73,781	Log normal	Yin et al. (2018)
Cardiovascular death c	77,811	58,358–97,263	Log normal	Wang et al. (2015), Yin et al. (2018)
Non-cardiovascular death	0	NA	NA	NA
Quality of life d
Initial event-free	0.824	0.800–0.848	β	Matza et al. (2015)
Non-fatal MI	0.672	0.625–0.719	β	Matza et al. (2015)
Post-MI	0.824	0.800–0.848	β	Matza et al. (2015)
Non-fatal IS	0.327	0.264–0.390	β	Matza et al. (2015)
Post-IS	0.524	0.472–0.576	β	Matza et al. (2015)
Injection site adverse reactions	−0.0003	−0.002-0	β	Khazeni et al. (2009)

CNY, Chinese Yuan; HR, hazard ratio; IS, ischemic stroke; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable; RR, relative risk.

^aThere was numerical but not significant reduction in cardiovascular mortality.

^bAll costs varied by ± 25% in the sensitivity analysis because confidence intervals were not available from the primary data sources and are presented in 2019 CNY.

^cCost of cardiovascular death was the weighted average cost of fatal MI and fatal stroke.

^dUtility values varied by 95% confidence intervals in the sensitivity analysis.